CENTESSA PHARMACEUTICALS (260) — Net Asset Quality Index
CENTESSA PHARMACEUTICALS (260) has a Net Asset Quality Index of 75.9% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €641.76 Million minus total liabilities of €154.41 Million yields net assets of €487.35 Million. A higher index indicates a stronger, lower-leverage balance sheet. Explore CENTESSA PHARMACEUTICALS (260) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
CENTESSA PHARMACEUTICALS Net Asset Quality Index Over Time (2021–2025)
This chart shows how CENTESSA PHARMACEUTICALS's Net Asset Quality Index has evolved across 5 annual periods from 2021 to 2025. As of March 2026, the index stands at 75.9%, representing net assets of €487.35 Million against total assets of €641.76 Million EUR. See 260 book value for net asset value and shareholders' equity analysis.
Annual Net Asset Quality Index for CENTESSA PHARMACEUTICALS (2021–2025)
The table below presents the year-by-year Net Asset Quality Index for CENTESSA PHARMACEUTICALS from 2021 to 2025, covering 5 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see how much is CENTESSA PHARMACEUTICALS worth.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 76.6% | €526.86 Million | €687.50 Million | €160.63 Million | ▲ +7.0 pp |
| 2024 | 69.6% | €401.55 Million | €576.80 Million | €175.25 Million | ▲ +4.0 pp |
| 2023 | 65.6% | €236.24 Million | €360.25 Million | €124.00 Million | ▼ -10.1 pp |
| 2022 | 75.7% | €336.17 Million | €444.31 Million | €108.14 Million | ▼ -2.4 pp |
| 2021 | 78.1% | €491.55 Million | €629.63 Million | €138.08 Million | — |